SV Health Investors
Presença
Executivos
Veja o organograma con seus 30 executivos principais
Biografias mais buscadas da SV Health Investors
- Eugene Hill, Chairman of the Board
- Mike Ross, Managing Partner, Biotechnology
- Brent Faduski, Chief Financial Officer, Chief Compliance Officer a...
Recentes movimentos de executivos em SV Health Investors
- Nikola Trbovic antes Partner, Biotechnology, foi promovido a Managing Partner, Biotechnology (Notícia publicada em 8 de janeiro de 2024).
- Jamil Beg, ingressou na Companhia como Partner, Biotechnology (Notícia publicada em 8 de janeiro de 2024).
Criar um alerta
para seguir os movimentos de executivos da SV Health Investors.
Fundo
SV Health Investors possui 1.474 concorrentes concorrentes Lloyds Development Capital (Reino Unido), BlackRock (Estados Unidos) e WindRose Health Investors (Estados Unidos).
Popular M&A news in Fundo
- Abrdn Private Equity Opportunities Trust mudará seu nome para Patria Capital Partners. (publicado em 30 de abril de 2024).
- HMC Capital adquiriu StratCap (publicado em 28 de fevereiro de 2024).
- Thomvest Ventures acaba de anunciar uma arrecadação de fundos de 250 milhões de dólares. (publicado em 17 de janeiro de 2024).
Outros contatos sugeridos na indústria do Fundo
- Antonio Gracias - Founder, Chief Executive Officer and Chief Investment Officer da Valor Equity Partners
- Mortimer Buckley - Chairman of the Board and Chief Executive Officer (retiring in Dec 2024) da Vanguard
- Jean-Marc Arbaud - President and Chief Executive Officer of CDPQ Infra da Caisse de Dépôt et Placement du Québec
Notícias
Últimos comunicados de imprensa de SV Health Investors
- Cerevance Adds $47 Million in Series B-1 Extension to Advance Robust Clinical Pipeline - SV Health Investors
- Harness Therapeutics Appoints Seasoned Biopharmaceutical Leader, Ms. Meenu Chhabra Karson, as Board Chair - SV Health Investors
- Former SV Portfolio Company Deciphera acquired by Ono Pharmaceutical for $2.4B after biotech's Phase 3 win - SV Health Investors
- SV Biotech launches its inaugural ESG and Impact Report - SV Health Investors
- Cumulus Neuroscience Receives Innovate UK Small Business Research Initiative (SBRI) Grant Focused on Clinical Biomarker Tools and Technologies for Dementia - SV Health Investors
- UK dementia adviser [Ruth McKernan] wants half a million volunteers for clinical trials - SV Health Investors
- Dementia Discovery Fund Look Ahead: 2024 is shaping up to be another big year in the fight against dementia - SV Health Investors
- Nitrase Therapeutics Unveils Pioneering Antibody Candidate for Parkinson’s Disease Based on Nitration Discovery in Oral Presentation at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD) Conference - SV Health Investors
- Prilenia Plans to Submit Marketing Authorization Application (MAA) in the EU for Pridopidine in Huntington’s Disease - SV Health Investors
- Cumulus Neuroscience Announces First Patient Enrolled in AccelADx Electroencephalogram (EEG) Study for Early Detection of Alzheimer's Dementia - SV Health Investors
- View more press releases Close
Redes sociais sobre SV Health Investors
- SV Health Investors na Wikipedia, Google News e Yahoo Finance
- SV Health Investors na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Eugene Hill 
Ligue para a SV Health Investors em +44 207...
